Quick answers
- What is Atenolol used for?
- The FDA-approved label (Tenormin, Upsher-Smith Laboratories, LLC, September 18, 2025) says: “Hypertension TENORMIN is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Atenolol have a boxed warning?
- The label we quote has no boxed warning, but 44 of 93 FDA labels for this medicine do. Check the label of your own product.
- Is there a shortage of Atenolol?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Atenolol been recalled?
- FDA enforcement reports list 3 recalls of products of this medicine; the newest started September 29, 2022 (Class I). A recall usually concerns specific lots, not every product.
- Who makes Atenolol?
- 31 companies list prescription products of Atenolol in the FDA NDC Directory, including A-S Medication Solutions, Bryant Ranch Prepack and NuCare Pharmaceuticals, Inc..
What Atenolol is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Hypertension TENORMIN is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. …
— FDA label: Tenormin, Upsher-Smith Laboratories, LLC, effective September 18, 2025. Read the full label on DailyMed →
The FDA has 93 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
44 of 93 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet |
|---|---|
| Route | Oral |
| Prescription products | 128 in the FDA NDC Directory |
| Brand names | Tenormin |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| atenolol 100 mg tablet | Generic | $0.0371 per tablet |
| atenolol 25 mg tablet | Generic | $0.0220 per tablet |
| atenolol 50 mg tablet | Generic | $0.0232 per tablet |
| atenolol 50 mg tablet | Brand: Tenormin | $12.78 per tablet |
NADAC list of November 4, 2026; these prices took effect between October 21, 2026 and October 28, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- A-S Medication Solutions14 products
- Bryant Ranch Prepack12 products
- NuCare Pharmaceuticals, Inc.10 products
- Preferred Pharmaceuticals Inc.7 products
- Northwind Health Company, LLC6 products
- Aphena Pharma Solutions - Tennessee, LLC5 products
- Proficient Rx LP5 products
- PD-Rx Pharmaceuticals, Inc.4 products
- Remedyrepack Inc.4 products
- St. Mary's Medical Park Pharmacy4 products
- Direct_Rx4 products
- Asclemed USA, Inc.3 products
- Safecor Health LLC3 products
- Zydus Pharmaceuticals USA Inc.3 products
- Mylan Institutional Inc.3 products
- Cardinal Health 107, LLC3 products
- Aurobindo Pharma Limited3 products
- Coupler LLC3 products
- Ipca Laboratories Limited3 products
- Teva Pharmaceuticals USA, Inc.3 products
- Upsher-Smith Laboratories, LLC3 products
- Unichem Pharmaceuticals (USA), Inc.3 products
- QPharma, Inc.3 products
- Rising Pharma Holdings, Inc.3 products
- Mylan Pharmaceuticals Inc.3 products
- Golden State Medical Supply, Inc.3 products
- Zydus Lifesciences Limited3 products
- NCS HealthCare of KY, LLC dba Vangard Labs2 products
- Major Pharmaceuticals1 product
- American Health Packaging1 product
- Quality Care Products, LLC1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA018240 TENORMIN | Twi Pharms | August 19, 1981 | 36, latest December 22, 2023 2023: Labeling · 2015: Manufacturing (CMC) · 2015: Manufacturing (CMC) |
Generic approvals (8)
- ANDA073026Pharmobedient · September 17, 1991
- ANDA073457Mylan · January 24, 1992
- ANDA074056Teva · January 18, 1995
- ANDA076900Zydus Pharms USA · January 28, 2005
- ANDA077443Unique · September 13, 2006
- ANDA077877Ipca Labs Ltd · December 27, 2006
- ANDA078512Aurobindo Pharma · October 31, 2007
- ANDA213136Unichem · November 21, 2019
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
September 29, 2022 · Class I · Terminated · D-0019-2023
Label Mix - up; a bottle labeled as Atenolol 25mg Tablets contained Clopidogrel 75mg Tablets
Atenolol Tablets, USP, 25 mg, 1000-count bottle, Rx only, Manufactured by: ALPHAPHARM PTY LTD, Marketed by: GSMS, Incorporated, Camarillo, CA 93012, USA, NDC 60429-027-10 — Golden State Medical Supply Inc.
-
March 6, 2017 · Class II · Terminated · D-0605-2017
Presence of Foreign Tablets/Capsules: Customer complaint that a bottle of atenolol 50 mg Tablets USP contained a paroxetine 20 mg tablet.
ATENOLOL Tablets, USP, 50 mg, packaged in a) 100-count bottles (NDC 68382-023-01) and b) 1000-count bottles (NDC 68382-023-10), Rx only, Manufactured by: Cadila Healthcare Ltd., India; Distributed by: Zydus Pharmaceutica — Zydus Pharmaceuticals USA Inc
-
August 5, 2014 · Class II · Terminated · D-0007-2015
Superpotent Drug: A complaint was reported by a pharmacist who stated several tablets were noticeably thicker in appearance.
ZyGenerics ATENOLOL Tablets, USP 25 mg 1000 count bottle, Rx Only Manufactured by: Cadila Healthcare Ltd. Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA Inc. Pennington, NJ 08634 USA NDC 68382-022-01 — Zydus Pharmaceuticals USA Inc
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Tenormin, Upsher-Smith Laboratories, LLC, effective September 18, 2025; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →